Generic Name and Formulations:
Elemental iron 30mg/mL (as ferumoxytol 510mg/17mL); colloidal iron for IV infusion after dilution; contains mannitol 44mg/mL; preservative-free.
Indications for FERAHEME:
Iron deficiency anemia in adults who have intolerance or insufficient response to oral iron; or have chronic kidney disease.
Give by IV infusion over at least 15mins. Initially 510mg, followed by a second 510mg dose 3–8 days later. May repeat treatment if condition persists or reoccurs. Hemodialysis: give at least 1hr after starting hemodialysis and after BP is stable.
<18yrs: not established.
History of any IV iron product allergy.
Risk of serious hypersensitivity/anaphylaxis reactions.
Risk of serious and fatal hypersensitivity reactions (including anaphylaxis). History of multiple drug allergies. Have equipment/personnel immediately available. Monitor for serious hypersensitivity reactions (including BP and pulse) during and after administration for ≥30mins and until clinically stable. Monitor for signs/symptoms of hypotension after each infusion. Iron overload: do not administer. Evaluate hemoglobin, ferritin, iron, transferrin saturation at least 1 month after 2nd infusion. Elderly. Pregnancy. Nursing mothers.
May reduce absorption of concomitant oral iron preparations. May transiently (up to 3mos) affect diagnostic ability of MRI (see full labeling). Concomitant chemotherapy or monoclonal antibodies: separate dosing by at least 30mins. Lab assays may overestimate serum iron and transferrin bound iron within 24hrs after administration.
Diarrhea, headache, nausea, dizziness, hypotension (may be severe), constipation, peripheral edema; hypersensitivity/anaphylaxis.
Single-use vials (17mL)—1, 10
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Genetic Counseling Recommended for Advanced Prostate Cancer
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Higher Doses of Image-Guided Neoadjuvant Radiation Therapy Found to Be Safe in Locally Advanced NSCLC: Study
- Supply Shortages of Bacillus Calmette-Guérin Found to Spur Drug Rationing in Non-Muscle-Invasive Bladder Cancer
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Epacadostat and Pembrolizumab Combo Active in Relapsed NSCLC
- PD-1 Inhibitor Cemiplimab Shows Antitumor Activity in Relapsed NSCLC